Key Highlights

  • TRex Bio (NASDAQ:TRXB) reported a third-quarter 2026 net loss of USD 13.2 million, up from USD 7.9 million a year earlier.
  • Research and development expense rose to USD 11.4 million from USD 7.0 million, while general and administrative costs were USD 2.5 million.
  • Cash, cash equivalents and marketable securities were USD 78.2 million at September 30, 2026, before IPO proceeds.
  • The October 2026 IPO sold 9,539,237 shares at USD 14.00 each, generating net proceeds of about USD 119.0 million.

Higher Research Spending Widens TRex Bio's Quarterly Loss

TRex Bio (NASDAQ:TRXB) filed its Quarterly Report for the period ended September 30, 2026, showing a net loss of USD 13.2 million against USD 7.9 million in the same quarter of 2025. Total operating expenses climbed to USD 13.9 million from USD 8.7 million, with Research and Development rising USD 4.5 million to USD 11.4 million and general and administrative expenses up USD 0.7 million to USD 2.5 million. Interest income was USD 0.8 million, slightly below USD 0.9 million a year earlier, and the company recorded a USD 0.1 million tax provision. For nine months, the net loss reached USD 42.5 million compared with USD 25.6 million, on operating expenses of USD 44.9 million. The company is a clinical-stage biopharmaceutical Business focused on tissue regulatory T cell biology, aiming to develop medicines for autoimmune and inflammatory diseases.

TRB-061 Moves Into Atopic Dermatitis Patients as Lilly Partnership Continues

The lead wholly owned candidate, TRB-061, is a TNF receptor 2 agonist designed to expand and activate regulatory T cells in inflamed tissue. After a Phase 1a study in healthy volunteers began in June 2025, the company advanced it into a Phase 1b portion in patients with moderate-to-severe atopic dermatitis in April 2026, with topline data expected in mid-2027. Direct spending on TRB-061 was USD 3.5 million in the quarter, up from USD 2.3 million. A second candidate, TRB-071, is in studies to support an IND application and is expected to start a Phase 1 trial in the first half of 2027, subject to regulatory allowance. Under a collaboration with Eli Lilly, the company remains eligible for up to USD 577.5 million in further milestones plus tiered royalties of 6% to 10% on net sales.

October IPO Reshapes the Balance Sheet and Cash Runway

The company completed its initial public offering in October 2026, selling 9,539,237 shares at USD 14.00 per share, including 1,205,903 shares from the underwriters' partial option exercise. Net proceeds were roughly USD 119.0 million after Underwriting discounts and offering costs. The September 30 financial statements do not reflect the offering, so the balance sheet still shows a stockholders' Deficit and an accumulated deficit of USD 136.8 million. Net loss per share was USD 10.06 for the quarter, calculated on the pre-IPO share count. Cash used in Operating Activities was USD 37.7 million for the nine months, and management believes existing resources plus IPO proceeds fund operations for at least twelve months. As of November 5, 2026, 28,788,654 shares of common stock were outstanding.

Where Things Stand

TRex Bio (NASDAQ:TRXB) is now a newly public company with a larger cost base and fresh capital. The quarterly loss widened as research spending climbed, and the reported cash balance of USD 78.2 million predates the USD 119.0 million IPO proceeds. The filing flags that more Capital would be needed beyond the twelve-month horizon if programs expand. The next markers are IND-enabling work on TRB-071, Phase 1b enrollment for TRB-061 and the mid-2027 topline readout.